Novo Nordisk A/S
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NVO research report →
Range $40 – $47
Price Chart
About the company
Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the innovation, development, production, and commercialization of pharmaceutical solutions. Its business is primarily divided into two key segments: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care segment offers a comprehensive portfolio of treatments for diabetes (including insulins, GLP-1 analogues, oral antidiabetic agents, and related delivery systems), obesity management, glucagon, medical needles, and other chronic conditions.
- CEO
- Maziar Mike Doustdar
- IPO
- 1981
- Employees
- 68,794
- HQ
- Bagsvaerd, CR, DK
Get TickerSpark's AI analysis on NVO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $169.23B
- P/E
- 10.36
- Fwd P/E
- 1.64
- PEG
- 1.11
- P/S
- 3.49
- P/B
- 5.35
- EV/EBITDA
- 7.13
- Div Yield
- 4.42%
- Gross Margin
- 80.79%
- Op Margin
- 42.39%
- Net Margin
- 33.92%
- ROE
- 54.14%
- ROIC
- 30.19%
Latest fiscal year · YoY change
- Revenue
- $309.06B+6.4%
- Gross Profit
- $250.28B+1.8%
- Op Income
- $127.66B
- Net Income
- $102.43B+1.4%
- EPS
- $23.06+1.7%
- OCF Growth
- -1.5%
- FCF Growth
- -58.4%
- 52W High
- $64.16
- 52W Low
- $35.12
- 50D MA
- $39.69
- 200D MA
- $42.91
- Beta
- 0.35
- RSI (14)
- 38
- Avg Volume
- 12.56M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Novo reported a strong Q3 with 4% sales growth, 27% operating profit growth, and another guidance raise, while management highlighted continued GLP-1 momentum, expanding oral launches, and a broadening late-stage pipeline.· November 4, 2026
- Adjusted sales rose 4% to DKK 79.2 billion; adjusted operating profit rose 27% in Q3, helped by GLP-1 growth and an easier comparison base.
- Novo raised 2026 guidance again: adjusted sales growth now -2% to +2% at CER, adjusted operating profit growth -2% to +2% at CER, and free cash flow is now expected at DKK 60 billion to DKK 70 billion.
- The company said it is reaching about 48 million people across diabetes and obesity, with obesity patients up to 5.6 million and obesity sales up 22% in the quarter.
- Wegovy pill momentum continued in both the U.S. and international markets, with early launches showing strong share and the oral franchise expanding to more markets.
- Pipeline updates centered on CagriSema, oral amycretin, Frehemgo, and other obesity and MASH programs, with several readouts and submissions expected through 2027-2028.
Q3 2026 adjusted sales increased 4% to DKK 79.2 billion. Adjusted operating profit increased 27% in the quarter, and management said the quarter included more than DKK 28 billion in free cash flow. Growth was driven by continued GLP-1 volume growth across U.S. and international operations, primarily in obesity; management also cited a favorable comparison base versus about DKK 9 billion of transformation costs in Q3 2025 and around DKK 3.5 billion of one-time costs in Q3 2026. For 2026, Novo now expects adjusted sales growth of -2% to +2% at CER, adjusted operating profit growth of -2% to +2% at CER, and free cash flow of DKK 60 billion to DKK 70 billion.
Mike Doustdar framed the quarter as evidence that Novo is in a “growth recovery phase,” pointing to sequential improvement in sales, a turnaround in patient volumes, and both operating units returning to growth. He emphasized the company’s 2030 ambition to deliver mid-single-digit sales CAGR and said Novo will now report progress against pipeline growth, sustainable growth, and shareholder returns. His tone was constructive and forward-looking, with repeated emphasis on launches as a source of energy and on getting CagriSema and Frehemgo to market quickly.
Karsten Munk Knudsen said Q3 adjusted sales were DKK 79.2 billion, adjusted operating profit rose 27%, and the quarter generated more than DKK 28 billion in free cash flow. He said the improved 2026 outlook is mainly driven by stronger expected GLP-1 product sales, while the profit outlook also reflects targeted investment in R&D and commercial activities funded in part by transformation savings and disciplined resource allocation. He highlighted that the company’s key 2026 modeling item is now free cash flow of DKK 60 billion to DKK 70 billion and noted the guidance range remains wide because the category is volatile and the company faces tougher Q4 comps, including about DKK 3 billion of U.S. gross-to-net in Q4 last year and more LOE impact in Canada.
Analysts focused heavily on whether the Bridge program is driving U.S. Wegovy growth, whether that growth can sustain into 2027, and how the company should think about pricing and payer pressure. Management said Bridge is contributing materially, with about 60,000 TRXs across injectable and oral, and that without Bridge the category would look relatively flat in the May-to-October period; they also said the 2027 setup includes pluses from pill uptake and new launches, but headwinds from international LOE, China, and less favorable gross-to-net. Other questions covered CagriSema’s brand halo, launch segmentation, oral rollout speed in international markets, and Ozempic pricing; management said CagriSema has a “medium” halo effect because it is more than semaglutide, and reiterated that U.S. diabetes pricing still typically erodes 10%-15% annually.
The bullish case from this call is that Novo is seeing sequential volume recovery, with both obesity and diabetes adding patients and international and U.S. operations back in growth. Management also pointed to strong early traction for the Wegovy pill, continued rollout of Wegovy 7.2 mg, and a deep pipeline with CagriSema, Frehemgo, oral amycretin, and other assets advancing.
The main risks discussed were pricing pressure, LOE in international markets, and uncertainty around how much of the U.S. momentum is tied to Bridge, which management said is meaningfully supporting growth and may not annualize cleanly. Analysts also pressed on whether payer resistance, Medicare access, and lower realized prices could limit future growth, while management acknowledged continued headwinds in China and potentially less favorable gross-to-net next year.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 70.5%
- Shares Outstanding
- 4.47B
- Float Shares
- 3.16B
of shares held by institutions
1,461 13F filers
Congressional trading
Senate and House stock disclosures for NVO, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Kevin HernHouse · OK01 | Sell | Aug 31, 26 | Filing → |
| Kevin HernHouse · OK01 | Sell | Sep 10, 26 | Filing → |
| Scott FranklinHouse · FL18 | Buy | Aug 26, 26 | Filing → |
| Scott FranklinHouse · FL18 | Buy | Aug 26, 26 | Filing → |
| Alan ArmstrongSenate | Buy | Mar 30, 26 | Filing → |
| Lisa C. McClainHouse · MI09 | Sell | Oct 31, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Buy | Oct 30, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Sell | Oct 30, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Buy | Sep 11, 25 | Filing → |
| Marjorie Taylor GreeneHouse · GA14 | Buy | Oct 15, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Sell | Aug 4, 25 | Filing → |
| Val HoyleHouse · OR04 | Buy | Oct 29, 24 | Filing → |
| Marjorie Taylor GreeneHouse · GA14 | Buy | Aug 28, 25 | Filing → |
| Marjorie Taylor GreeneHouse · GA14 | Buy | Aug 19, 25 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Dodge & Cox | 20.35M | ▼ 44.65K |
| Loomis Sayles & Co L P | 17.85M | ▼ 743.24K |
| Arrowstreet Capital, Limited Partnership | 17.09M | ▲ 8.82M |
| Two Sigma Investments, LP | 14.91M | ▲ 14.90M |
| Bank Of America Corp | 13.53M | ▲ 2.35M |
| Franklin Templeton Inc | 13.47M | ▲ 431.38K |
| Morgan Stanley | 13.01M | ▲ 1.35M |
| Folketrygdfondet | 9.46M | ▼ 61.52K |
| Capital International Investors | 9.46M | ▼ 263.91K |
| Fisher Asset Management, LLC | 7.95M | ▼ 375.48K |
| Citadel Advisors LLC | 7.01M | ▲ 5.65M |
| Everett Harris & Co | 6.47M | ▼ 7.13K |
Held by 58 ETFs
Biggest fund positions in NVO by dollar value.
Our NVO coverage
Recent articles, reports, and earnings notes.

Novo Nordisk (NVO): GLP-1 Growth Meets Price Pressure
Novo Nordisk still has a powerful obesity and diabetes franchise, but slower growth, pricing pressure, and tougher competition have shifted the stock into a Hold case. Wegovy momentum and strong profitability support the thesis, while valuation is now close to fair value.

Should You Buy Corxel US Before the SPAC Merger Closes?
Corxel US is a clinical-stage biopharmaceutical company developing oral obesity and cardiometabolic therapies, and it is going public through a merger with Amanat Acquisition Corp. (Nasdaq: AMAN). The deal is expected to close in the first half of 2027, but shareholders should watch the cash raise and redemption math closely because dilution and trust leakage could reshape the setup.

Novo Nordisk A/S (NVO) drops on Investor Day doubts
Novo Nordisk A/S (NVO) drops after its Capital Markets Day failed to calm investor worries about semaglutide’s patent cliff and tougher competition from Eli Lilly. The company still posted solid earnings and outlined a large pipeline plan, but the market wants clearer near-term growth beyond its blockbuster obesity and diabetes drugs.
Want a deeper read on NVO?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Forget the Headlines: Novo Nordisk's (NVO) 4.6% Dividend Yield Is the Real Story for Patient Investors
fool.com · Nov 20
Novo Nordisk: A Return To Growth May Be Just Around The Corner
seekingalpha.com · Nov 19
Weight-loss drugs' hit to UK grocery spending tops £1 billion, Worldpanel says
reuters.com · Nov 18
Novo Nordisk: The Worst May Be Behind
seekingalpha.com · Nov 18
Eli Lilly vs. Novo Nordisk: Which GLP-1 Stock Is a Better Buy for 2027?
fool.com · Nov 17
Novo Nordisk: The Thesis Is Working, The Stock Just Hasn't Noticed Yet
seekingalpha.com · Nov 17
Johnson & Johnson vs. Novo Nordisk: Steady Uptrend vs.
fool.com · Nov 17
NVO's Hemophilia A Treatment Gets EC Nod, Data Presented on CagriSema
zacks.com · Nov 16
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.